Abstract
Multidrug resistance (MDR) in a variety of human tumours such as renal cell carcinoma (RCC) is thought to be caused by expression of theMDR1 gene and may be reversed by applying modern chemosensitisers such as dexverapamil, which inhibit theMDR1 gene product P-glycoprotein. This preliminary report gives information on a clinical study complying with good clinical practice regulations in patients with advanced RCC. The final evaluation is pending. Vinblastine, if anything the most effective chemotherapeutic agent (5-day continuous regimen), was combined with oral dexverapamil (6 times per day) as a chemosensitiser and dexamethasone to increase dexverapamil tolerance. All patients had histologically proven RCC, which was metastatic and progressive at study entry. The statistical design featured a pre-study regimen of two cycles of vinblastine alone followed by evaluation. If no response was documented, with all patients thus serving as their own control, dexverapamil and dexamethasone were added for three cycles of combination therapy. Having obtained institutional permission from the ethical review committee, we enrolled patients of whom 25 qualified for the combined-treatment arm; 13 patients finished the study, 5 patients failed to complete all treatment cycles (1 because of treatment-related toxicity, 3 for personal reasons, not related to treatment, 1 for tumour-related reasons) and 7 patients were at too early a stage for evaluation. Altogether, 61% of all patients tolerated a dose of dexverapamil of at least 2400 mg/day with peak serum levels reaching, in some cases, approximately 8 μM (the sum of dexverapamil plus nordexverapamil levels). WHO grade 3 and 4 toxicities were mainly myelosuppression (5/18). The combination of 1.4 mg m−2 day−1 vinblastine plus dexverapamil was generally felt to be safe and well tolerated. One partial response and 7 stable diseases were noted in this heavily pretreated study population. Four-hourly administration of dexverapamil in combination with dexamethasone plus escalation to the individually tolerated doses have permitted increases in serum levels of dexverapamil.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bissett D, Kerr DJ, Cassidy J (1991) Phase I and pharmacokinetic study ofd-verapamil and doxorubicin. Br J Cancer 64:1168–1171
Fan D, Beltran PJ, O'Brian CA (1994) Reversal of multidrug resistance. In: Kellen JA (ed) Reversal of multidrug resistance in cancer. CRC Press, Boca Raton, Fl, pp 93–125
Fojo AT, Shen D-W, Pastan I, Gottesman MM (1987) Intrinsic drug resistance in kidney cancers is associated with expression of a human multidrug resistance gene. J Clin Oncol 5:1922–1927
Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346–353
Gehling U, Weimar C, Schuler U, Rathgeb R, Ehninger G, Schumacher K, Havemann K (1993) A pilot study with dexniguldipine and doxorubicin in patients with metastatic hypernephroma. Onkologie 16 [Suppl]:25
Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427
Gottesman MM, Mickisch GH, Pastan I (1994) In vivo models of P-glycoprotein-mediated multidrug resistance, In: Goldstein L, Ozols (eds) Anticancer drug resistance. Kluwer, Norwell, Massachusetts, p 103
Häußermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M (1990) Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 40:53–59
Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I (1988) Measurement of multidrug resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 139:862–865
Lehnert M (1994) Reversal of P-glycoprotein-associated multidrug resistance: from bench to bedside. Onkologie 17:8–15
Merry S, Flanigan P, Schlick E, Freshney RI, Kaye SB (1989) Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil. Br J Cancer 59:895–897
Mickisch GH (1994) Chemoresistance of renal cell carcinoma: 1986–1994. World J Urol 12:214–223
Mickisch G, Kössig J, Keilhauer G, Schlick E, Tschada R, Alken P (1990) Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 50:3670–3674
Mickisch G, Merlino GT, Galski H, Gottesman MM, Pastan I (1991) Transgenic mice that express the human multidrug resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 88:547–551
Overmoyer B, Fox K, Tomaszewski J, Malkowicz S, MacDermott M, Kay A, Spigelman M, Schuchter L (1993) A phase II trial ofR-verapamil and infusional vinblastine (velban) in advanced renal cell carcinoma (RCC) (abstract). Proc Am Soc Clin Oncol 12:251
Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parillo JE, Young RC (1987) Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641–647
Raderer M, Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553–3563
Rodenburg CJ, Nooter K, Herweijer H, Seynaeve C, Oosterom R, Stoter G, Verweij J (1991) Phase II study of combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2:305–306
Schumacher K, Ladda E, Bühl K, Weimer A, Eser C, Hamprecht K, Traugott U, Roller E, Schalk KP, Eichelbaum M (1991)R-Verapamil, a modulator of multidrug resistance: phase I clinical trial. J Cancer Res Clin Oncol 117 [Suppl]:113
Sikic B (1993) Modulation of multidrug resistance: at the threshold. J Clin Oncol 11:1629–1635
Tolcher AW, Cowam KH, Solomon D, Berg S, Venzon D, Goldspiel B, Barnes C, Noone M, Gossard M, Chang R, Ognibeno F, O'Shaugnessy JA (1994) A phase I study of paclitaxel (T) withR-verapamil (RV) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 13: 349
Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248–24252
Van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone G (1991) Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 67:284–289
Wilson WH, Bates S, Kang YK, Fojo A, Bryant G, Wittes R, Stevenson MA, Steinberg S, Chabner BA (1993) Reversal of multidrug resistance (mdr-1) withR-verapamil and analysis of mdr-1 expression in patients with lymphoma refractory to EPOCH chemotherapy. Proc Am Assoc Cancer Res 3: 212
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mickisch, G.H., Noordzij, M.A., Gaast, A.v.d. et al. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 121 (Suppl 3), R11–R16 (1995). https://doi.org/10.1007/BF02351065
Issue Date:
DOI: https://doi.org/10.1007/BF02351065